Cohen Stephanie A, Tan Christopher A, Bisson Ryan
Cancer Genetics Risk Assessment Program, St. Vincent Health Indianapolis, IN, USA.
Invitae Corporation San Francisco, CA, USA.
Front Genet. 2016 Mar 16;7:36. doi: 10.3389/fgene.2016.00036. eCollection 2016.
The utilization of next-generation sequencing technology to interrogate multiple genes simultaneously is being utilized more frequently in hereditary cancer testing. While this has benefits of reducing cost and allowing clinicians to cast a wide net in the elucidation of their patient's cancer, panel testing has the potential to reveal unexpected information. We report on a proband with pathogenic variants resulting in two different hereditary colon cancer syndromes. A 39-year-old male with a history of colon cancer, more than 20 colon polyps and a family history of colon cancer presented for genetic counseling. Testing with a 7-gene high-risk hereditary colon cancer panel identified a homozygous pathogenic variant, c.1187G>A (p.Gly396Asp) in MUTYH, and a likely pathogenic duplication of exon 7 in MSH2. Since this test result, the proband's mother was diagnosed with colon cancer; subsequent genetic testing confirmed she also carries the likely pathogenic duplication in the MSH2 gene. Although the cancer risk in individuals who carry multiple pathogenic variants has not been established for combined biallelic MUTYH-associated polyposis and Lynch syndrome, the identification of multiple pathogenic variants does allow for screening for cancers associated with both syndromes and has implications for cancer risk for family members. In particular, this has significant impact on those who test negative for a known familial pathogenic variant, yet could be still be at risk for cancer due to a second pathogenic variant in a family. More information is needed on the frequency of occurrence of multiple pathogenic variants, as well as the phenotypic spectrum when multiple pathogenic variants are present.
在遗传性癌症检测中,利用下一代测序技术同时检测多个基因的情况越来越普遍。虽然这具有降低成本的好处,并使临床医生能够在阐明患者癌症病因时进行广泛排查,但基因 panel 检测有可能揭示意想不到的信息。我们报告了一名携带致病变异导致两种不同遗传性结肠癌综合征的先证者。一名39岁男性,有结肠癌病史、20多个结肠息肉以及结肠癌家族史,前来进行遗传咨询。使用包含7个基因的高危遗传性结肠癌 panel 检测发现,MUTYH 基因存在纯合致病变异 c.1187G>A(p.Gly396Asp),MSH2 基因外显子7存在可能致病的重复。自该检测结果出来后,先证者的母亲被诊断出患有结肠癌;随后的基因检测证实她也携带 MSH2 基因可能致病的重复。虽然对于双等位基因 MUTYH 相关息肉病和林奇综合征患者携带多种致病变异时的癌症风险尚未明确,但多种致病变异的鉴定确实有助于筛查与这两种综合征相关的癌症,并对家庭成员的癌症风险具有重要意义。特别是,这对那些已知家族致病变异检测呈阴性,但由于家族中存在第二个致病变异仍可能有患癌风险的人有重大影响。关于多种致病变异的发生频率以及存在多种致病变异时的表型谱,还需要更多信息。